The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

BACKGROUND: Chronic kidney disease (CKD) is a common complication of type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and lower body weight in people with T2D, and some reduce the risk of cardiovascular (CV) events in those with high CV risk. GLP-...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossing, Peter, Baeres, Florian M M, Bakris, George, Bosch-Traberg, Heidrun, Gislum, Mette, Gough, Stephen C L, Idorn, Thomas, Lawson, Jack, Mahaffey, Kenneth W, Mann, Johannes F E, Mersebach, Henriette, Perkovic, Vlado, Tuttle, Katherine, Pratley, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469096/
https://www.ncbi.nlm.nih.gov/pubmed/36651820
http://dx.doi.org/10.1093/ndt/gfad009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469096/
https://www.ncbi.nlm.nih.gov/pubmed/36651820
http://dx.doi.org/10.1093/ndt/gfad009

Ejemplares similares